WW INTERNATIONAL INC (WW)
NASDAQHealth CarePersonal Products & ServicesSnapshot 2026-10-29
$14.90-1.00%
Close 2026-10-30 · 1-day change
NASDAQHealth CarePersonal Products & ServicesSnapshot 2026-10-29
Research Workspace
Put WW beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — WW revenue near $628 million in FY26: Revenue guidance: $620M to $635M.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 74% in its worst 12-month stretch.
View RiskWW’s clinical and behavioral subscriber growth is the recovery bet, supported by GLP-1 care momentum. Q2 FY2026 revenue grew 30.4% year over year, and earnings beat consensus. Revenue guidance is $620 million to $635 million for FY26, with the thesis pillar under pressure. WW trades at 0.2× sales versus the 1.0× peer median. The price reflects less growth than our forecast, though weak cash backing clouds reported profits. A next-quarter miss probability of 40% makes execution a specific risk. Peer multiples imply a price about 79% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. WW is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering WW (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare WW with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| WW Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Compare the value case
Put WW next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Grow Clinical and Behavioral subscriber base
GLP-1 care gains momentum supports subscriber growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Manage CEO and Board transitions with experienced hires
New CEO aligns with management's transition objective.
Advances: Grow Clinical and Behavioral subscriber base
Reaffirmation of revenue outlook supports subscriber growth.
Advances: Grow Clinical and Behavioral subscriber base
Revenue beat indicates positive momentum for growth.
Partnership with Walmart enhances brand visibility and potential customer base.
Advances: Grow Clinical and Behavioral subscriber base
New partnership supports growth in clinical subscriber base.
Advances: Grow Clinical and Behavioral subscriber base
Expansion of clinical services aligns with growth objectives.
Advances: Grow Clinical and Behavioral subscriber base
Strong Q1 performance supports growth in subscriber base.